Shorter TB treatment for adults in Kazakhstan
Part of Infections clinical trials.
This study tests shorter treatment plans for tuberculosis (TB) in Kazakhstan. It aims to see if a newer drug combination can cure TB or TB infection faster and with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must live in one of the four pilot regions of Kazakhstan.
- If you have TB disease, it must be newly diagnosed and not drug-resistant.
- If you have TB infection (not active disease), you cannot have had TB treatment in the last 2 years.
- You cannot be pregnant or breastfeeding for most parts of the study.
- You must have a working phone for follow-up calls.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
This study tests ways to help people who live with or are close to someone with tuberculosis get medicine to prevent them from getting sick. It aims to improve how many people start and finish this preventive treatment in Tajikistan and Tanzania.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.